Anastasios Stathis
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica 2024
20.06.2024A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
20.06.2024Haematologica 2024
Spriano Filippo, Sartori Giulio, Sgrignani Jacopo, Barnabei Laura, Arribas Alberto, Guala Matilde, Del Amor Ana Maria Carrasco, Tomasso Meagan R, Tarantelli Chiara, Cascione Luciano, Golino Gaetanina, Riveiro Maria E, Bortolozzi Roberta, Lupia Antonio, Paduano Francesco, Huguet Samuel, Rezai Keyvan, Rinaldi Andrea, Margheriti Francesco, Ventura-Aguiar Pedro, Guarda Greta, Costa Giosuè, Rocca Roberta, Furlan Alberto, Verdonk Luuk M, Innocenti Paolo, Martin Nathaniel I, Viola Giampietro, Driessen Christoph, Zucca Emanuele, Stathis Anastasios, Gahtory Digvijay, Van den Nieuwboer Maurits, Bornhauser Beat, Alcaro Stefano, Trapasso Francesco, Cristobal Susana, Padrick Shae B, Pazzi Natalina, Cavalli Franco, Cavalli Andrea, Gaudio Eugenio, Bertoni Francesco
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna G, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodón J, Ahn M, Kim H, Schneeweiss A, Ribera J, DeAngelo D, Perez Garcia J, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl F, Garralda E. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun 2023; 3:1853-1861.
14.09.2023A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
14.09.2023Cancer Res Commun 2023; 3:1853-1861
Hanna Glenn J, Stathis Anastasios, Lopez-Miranda Elena, Racca Fabricio, Quon Doris, Leyvraz Serge, Hess Dagmar, Keam Bhumsuk, Rodón Jordi, Ahn Myung-Ju, Kim Hye Ryun, Schneeweiss Andreas, Ribera Josep-Maria, DeAngelo Daniel, Perez Garcia Jose Manuel, Cortes Javier, Schönborn-Kellenberger Oliver, Weber Dirk, Pisa Pavel, Bauer Michael, Beni Laura, Bobadilla Maria, Lehal Raj, Vigolo Michele, Vogl Florian D, Garralda Elena
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023; 41:267-275.
16.02.2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
16.02.2023Invest New Drugs 2023; 41:267-275
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
12.07.2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
12.07.2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14
27.04.2022Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
27.04.2022Cancers (Basel) 2022; 14
Jörger Markus, Metaxas Yannis, Zaman Khalil, Michielin Olivier, Mach Nicolas, Bettini Adrienne, Schmitt Andreas M, Cantoni Nathan, Caspar Clemens B, Stettler Sonja, Malval Roma, Pless Miklos, Britschgi Christian, Renner Christoph, Koeberle Dieter, Schulz Jessica D, Kopp Christoph, Hayoz Stefanie, Stathis Anastasios, von Moos Roger, Swiss Group for Clinical Cancer Research (SAKK)
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa M, Cittone M, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista M, Bastidas G, Beà S, Boldorini R, Broccoli A, Buehler M, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia A, Facchetti F, Gaidano G, Garcia J, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier D, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer J, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani P, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, de Leval L, Dirnhofer S, Pileri S, Piris M, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022; 139:732-747.
03.02.2022Genetic and phenotypic attributes of splenic marginal zone lymphoma.
03.02.2022Blood 2022; 139:732-747
Bonfiglio Ferdinando, Bruscaggin Alessio, Guidetti Francesca, Terzi di Bergamo Lodovico, Faderl Martin Richard, Spina Valeria, Condoluci Adalgisa, Bonomini Luisella, Forestieri Gabriela, Koch Ricardo, Piffaretti Deborah, Pini Katia, Pirosa Maria Cristina, Cittone Micol Giulia, Arribas Alberto, Lucioni Marco, Ghilardi Guido, Wu Wei, Arcaini Luca, Baptista Maria Joao, Bastidas Gabriela, Beà Silvia, Boldorini Renzo, Broccoli Alessandro, Buehler Marco, Canzonieri Vincenzo, Cascione Luciano, Ceriani Luca, Cogliatti Sergio, Corradini Paolo, Derenzini Enrico, Devizzi Liliana, Dietrich Sascha, Elia Angela Rita, Facchetti Fabio, Gaidano Gianluca, Garcia Juan Fernando, Gerber Bernhard, Ghia Paolo, Gomes da Silva Maria, Gritti Giuseppe, Guidetti Anna, Hitz Felicitas, Inghirami Giorgio, Ladetto Marco, López-Guillermo Armando, Lucchini Elisa, Maiorana Antonino, Marasca Roberto, Matutes Estella, Meignin Véronique, Merli Michele, Moccia Alden, Mollejo Manuela, Montalban Carlos, Novak Urban, Oscier David Graham, Passamonti Francesco, Piazza Francesco A, Pizzolitto Stefano, Rambaldi Alessandro, Sabattini Elena, Salles Gilles Andre, Santambrogio Elisa, Scarfo Lydia, Stathis Anastasios, Stussi Georg, Geyer Julia Turbiner, Tapia Gustavo, Tarella Corrado, Thieblemont Catherine, Tousseyn Thomas, Tucci Alessandra, Vanini Giorgio, Visco Carlo, Vitolo Umberto, Walewska Renata, Zaja Francesco, Zenz Thorsten, Zinzani Pier Luigi, Khiabanian Hossein, Calcinotto Arianna, Bertoni Francesco, Bhagat Govind, Campo Elias, de Leval Laurence, Dirnhofer Stefan, Pileri Stefano A, Piris Miguel A, Traverse-Glehen Alexandra, Tzankov Alexander, Paulli Marco, Ponzoni Maurilio, Mazzucchelli Luca, Cavalli Franco, Zucca Emanuele, Rossi Davide
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Pirosa M, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2021; 63:117-123.
19.08.2021A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
19.08.2021Leuk Lymphoma 2021; 63:117-123
Pirosa Maria C, Zhang Lu, Hitz Felicitas, Novak Urban, Hess Dagmar, Terrot Tatiana, Pascale Mariarosa, Mazzucchelli Luca, Bertoni Francesco, Cavalli Franco, Zucca Emanuele, Stathis Anastasios
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Invest New Drugs 2019
30.08.2019A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
30.08.2019Invest New Drugs 2019
Jörger Markus, Sessa Cristiana, Stuedeli Silvia, Levy Nicole, Hafner Peter, Lane Heidi, Larger Patrice, Engelhardt Marc, Kaindl Thomas, Volden Matthias, Mark Michael, Mantiero Mara, Hess Dagmar, Metaxas Yannis, Stathis Anastasios, von Moos Roger
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017
16.06.2017Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
16.06.2017Hematol Oncol 2017
Gobba Stefania, Gaidano Gianluca, Pinotti Graziella, Hitz Felicitas, Stathis Anastasios, Aprile von Hohenstaufen Kathrin, Margiotta-Casaluci Gloria, Iacoboni Gloria, Cascione Luciano, Diem Stefan, Conconi Annarita, Gulden-Sala Wiebke, Moccia Alden A, Zucca Emanuele
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, Stathis A, Fischer N, Clough-Gorr K. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. Support Care Cancer 2017; 25:2833-2842.
13.04.2017Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
13.04.2017Support Care Cancer 2017; 25:2833-2842
Ribi Karin, Rondeau Stephanie, Hitz Felicitas, Mey Ulrich, Enoiu Milica, Pabst Thomas, Stathis Anastasios, Fischer Natalie, Clough-Gorr Kerri M